ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 83.6 | 158.6 | 91.1 |
| Other income | 0.7 | 2.6 | 0.5 |
| Total income | 84.3 | 161.3 | 91.6 |
| Profit before exceptional items & tax | -18.7 | -7.9 | -33.0 |
| Profit before tax | -18.7 | -7.9 | -33.0 |
| Net profit | -18.7 | -7.7 | -33.0 |
| Operating margin | -22.2% | -4.9% | -36.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | -8.20% |
|---|---|
| Operating profit, year on year | +42.10% |
| Operating profit, quarter on quarter | -88.30% |
BSE results filing, NSE: ASTEC. Figures extracted from the filing.
Astec Lifesciences Ltd: key numbers
- Share price
- ₹535.30
- Market cap
- ₹1,193 Cr
- Revenue (annual)
- ₹448.1 Cr
- Net profit (annual)
- ₹-80.92 Cr
- P/E (TTM)
- -15.0×Sector 35.5×
- Promoter holding
- 71.96%+0.00% QoQ
- FII holding
- 0.02%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Astec Lifesciences Ltd
All →Astec Lifesciences Price Movement Clarification
Astec LifeSciences replied to a BSE volume-movement query confirming no undisclosed price-sensitive developments. The company affirmed full compliance with Listing and PIT Regulations.
Astec Lifesciences Results Update
Astec LifeSciences released a press release on its Q2 and H1 FY27 results, approved October 26, 2026. Q2 FY27 losses widened year on year.
Astec Lifesciences Other Announcement
Astec LifeSciences filed a Reg 54 Nil Security Cover certificate for its listed unsecured NCDs, stating the security cover format is not applicable. This is routine compliance paperwork with no new money or business event.
Astec Lifesciences Q2 FY27 Results: Net Loss of ₹37.4 Cr, Loss Widens
Astec Lifesciences Ltd reported revenue from operations of ₹72 Cr (-2.3% YoY) and a net loss of ₹37.4 Cr for Q2 FY27.
- Key figure
- Net loss ₹37.4 Cr
Astec Lifesciences Board Meeting Date
Astec LifeSciences will hold a board meeting on October 26, 2026, to consider and approve standalone and consolidated unaudited financial results for the half-year ending September 2026.
Astec Lifesciences Other Announcement
Astec Lifesciences Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as per regulatory requirements.